August 6, 2020 – South Burlington, VT
Data Innovations has partnered with Next Generation Sequencing (NGS) platform provider, Varstation, to design and develop an instrument driver for a São Paulo, Brazil-based research hospital in support of a new COVID-19 genetic test. The new test is based on Next Generation Sequencing (NGS) which reads small fragments of DNA to identify diseases based on genetic alterations. The new Instrument Manager driver from Data Innovations helps ensure accurate and automated transmission of test results between the Varstation platform and the hospital’s Laboratory Information System (LIS).
“Data Innovations is proud to support our Brazilian customer and Varstation with an innovative solution to assist in the global response to the COVID-19 pandemic. This is a great example of the work done by our teams around the world during the past five months to automate COVID-19 workflows and testing.” said Premila Peters, President, Data Innovations.
In partnering with Data Innovations, Varstation and the Brazilian hospital were able to expand on and leverage the existing use of Data Innovations Instrument Manager solution. In addition to the Varstation driver developed specifically to support integration of this platform with Instrument Manager, Data Innovations has more than 50 other drivers available that are specifically associated with COVID-19 testing.
About Data Innovations
Data Innovations provides lab enablement software and solutions for clinical labs to optimize performance across all disciplines. With key solutions spanning lab connectivity, productivity, quality, performance and reliability, and analytics, Data Innovations is credited with establishing the lab enablement software space and driving vendor-neutral solutions within and across labs. They are a global software company, serving 6,000+ hospitals and laboratories in 85+ countries.
Varstation manages complex genetic data and provides increasingly accurate results for the diagnosis and treatment of patients. We offer post-sequencing computational and clinical interpretation support at affordable prices so that accessible genetics can become a reality in the health area.